Advanced

Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18

Villa, Luisa L.; Ault, Kevin A.; Giuliano, Anna R.; Costa, Ronaldo L. R.; Petta, Carlos A.; Andrade, Rosires P.; Brown, Darron R.; Ferenczy, Alex; Harper, Diane M. and Koutsky, Laura A., et al. (2006) In Vaccine 24(27-28). p.5571-5583
Abstract
Human papillomavirus (HPV) infection causes cervical cancer and genital warts. Young women (1106) were randomized to receive one of three formulations of a quadrivalent HPV (Types 6/11/16/18) L1 virus-like particle (VLP) vaccine or one of two placebo formulations. The goal was to assess vaccine safety and immunogenicity in baseline HPV 6/11/16 or 18-naive and previously infected subjects. All three formulations were highly immunogenic. At Month 2 (postdose 1), among women with vaccine-type antibodies at baseline, vaccine-induced anti-HPV responses were similar to 12- to 26-fold higher than those observed in baseline-naive women, suggesting an anamnestic response. Following an initial, similar sized decline, anti-HPV responses plateaued and... (More)
Human papillomavirus (HPV) infection causes cervical cancer and genital warts. Young women (1106) were randomized to receive one of three formulations of a quadrivalent HPV (Types 6/11/16/18) L1 virus-like particle (VLP) vaccine or one of two placebo formulations. The goal was to assess vaccine safety and immunogenicity in baseline HPV 6/11/16 or 18-naive and previously infected subjects. All three formulations were highly immunogenic. At Month 2 (postdose 1), among women with vaccine-type antibodies at baseline, vaccine-induced anti-HPV responses were similar to 12- to 26-fold higher than those observed in baseline-naive women, suggesting an anamnestic response. Following an initial, similar sized decline, anti-HPV responses plateaued and remained stable through end-of-study (3.0 years). No vaccine-related serious adverse experiences were reported. (c) 2006 Elsevier Ltd. All rights reserved. (Less)
Please use this url to cite or link to this publication:
@article{760c5f58-3cdd-455f-a504-505620edefd2,
  abstract     = {Human papillomavirus (HPV) infection causes cervical cancer and genital warts. Young women (1106) were randomized to receive one of three formulations of a quadrivalent HPV (Types 6/11/16/18) L1 virus-like particle (VLP) vaccine or one of two placebo formulations. The goal was to assess vaccine safety and immunogenicity in baseline HPV 6/11/16 or 18-naive and previously infected subjects. All three formulations were highly immunogenic. At Month 2 (postdose 1), among women with vaccine-type antibodies at baseline, vaccine-induced anti-HPV responses were similar to 12- to 26-fold higher than those observed in baseline-naive women, suggesting an anamnestic response. Following an initial, similar sized decline, anti-HPV responses plateaued and remained stable through end-of-study (3.0 years). No vaccine-related serious adverse experiences were reported. (c) 2006 Elsevier Ltd. All rights reserved.},
  author       = {Villa, Luisa L. and Ault, Kevin A. and Giuliano, Anna R. and Costa, Ronaldo L. R. and Petta, Carlos A. and Andrade, Rosires P. and Brown, Darron R. and Ferenczy, Alex and Harper, Diane M. and Koutsky, Laura A. and Kurman, Robert J. and Lehtinen, Matti and Malm, Christian and Olsson, Sven-Eric and Ronnett, Brigitte M. and Skjeldestad, Finn Egil and Steinwall, Margareta and Stoler, Mark H. and Wheeler, Cosette M. and Taddeo, Frank J. and Yu, Jimmy and Lupinacci, Lisa and Railkar, Radha and Marchese, Rocio and Esser, Mark T. and Bryan, Janine and Jansen, Kathrin U. and Sings, Heather L. and Tamms, Gretchen M. and Saah, Alfred J. and Barr, Eliav},
  issn         = {1873-2518},
  keyword      = {immunogenicity,human papillomavirus,vaccine},
  language     = {eng},
  number       = {27-28},
  pages        = {5571--5583},
  publisher    = {Elsevier},
  series       = {Vaccine},
  title        = {Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18},
  url          = {http://dx.doi.org/10.1016/j.vaccine.2006.04.068},
  volume       = {24},
  year         = {2006},
}